In this article

PFE

Follow your favorite stocks CREATE FREE ACCOUNT

President Donald Trump 's long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared , following his new drug-pricing deal with Pfizer .

Trump's Tuesday agreement with the company to voluntarily lower U.S. drug prices included a three-year exemption from pharmaceutical-specific tariffs, as long as the firm further invests in domestic manufacturing. Pfizer on Tuesday pledged to put $70 billion into U.S. manufacturing and research, on top of previous investments.

That deal brought relief and clarity to Pfizer and the broader pharmaceutical industry, signaling that many drugmakers could strike similar deals that would make them immune to the levi

See Full Page